Edwards Lifesciences Corp. closed 23.74% short of its 52-week high of $96.12, which the company achieved on March 28th.

Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

A federal court granted summary judgment to Edwards Lifesciences LLC on a Title VII failure to accommodate religious observance claim of a senior cardiovascular specialist who alleged that Edwards ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat. On Tuesday, Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales ...

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Edwards Lifesciences (EW – Research Report), with a price ...

Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they ...

This was the stock's second consecutive day of losses.